The shares of this leading pharmaceutical company are in focus after the company secured the USFDA’s approval for its key drug used to treat ovarian cancer. In this article, we will dive deep into its details.
With a market capitalisation of Rs 20,494 crores, the shares of Alembic Pharmaceuticals Ltd are currently trading at Rs 1,043 per share, down by 19.53 percent from its 52-week high of Rs 1,296.15 per share. Over the past five years, the stock has delivered a poor return of 13.58 percent.
The firm disclosed in a stock exchange document that it has been granted final clearance from the US FDA for its generic version of Doxorubicin Hydrochloride Liposome Injection.
The drug will be supplied in 20 mg/10 mL and 50 mg/25 mL single-dose vials. The approved drug is said to be equivalent to the branded name, Doxil, produced by Baxter Healthcare, as it can be used as a substitute for the same treatment.
Doxorubicin Hydrochloride Liposome Injection is a treatment option for Ovarian Cancer, AIDS-related Kaposi’s Sarcoma, and Multiple Myeloma. This drug works by slowing down or halting the growth of cancer cells. The liposomal formulation is designed to minimize side effects by delivering the medication more directly to the cancer cells.
Financial Highlights
The company reported a revenue of Rs 6,672 crores in FY25, up by 7.11 percent from its FY24 revenue of Rs 6,229 crores. However, the company reported a net profit decline of 5.51 percent to Rs 582 crore in FY25 from Rs 616 crores in FY24.
The stock delivered an ROE and ROCE of 11.35 percent and 13.05 percent, respectively, and is currently trading at a P/E of 36.08x as compared to its industry average of 32.71x.
Alembic Pharmaceuticals Limited manufactures and markets generic pharmaceutical products all over the world. Alembic’s state-of-the-art research and manufacturing facilities are approved by regulatory authorities of many developed countries, including the USFDA. Alembic is one of the leaders in branded generics in India. Alembic’s brands, marketed through a field force of over 5500, are well recognized by doctors and patients.
Written by Satyajeet Mukherjee
Disclaimer
The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
